GlobeNewsWire · ADIL · October 16, 2026

Adial Pharmaceuticals Appoints David Rubenstein, M.D., Ph.D., as Chief Scientist to Advance its Colon-Targeted AhR Agonist, AT177, for Ulcerative Colitis

Get the app for more

Explore stock news, insights and company research.